Into the light? Diabetic nephropathy and vitamin D

被引：24

作者：

Thomas, Merlin C. ^{[1
,2
]}

Cooper, Mark E. ^{[1
]}

机构：

[1] Baker IDI Heart & Diabet Inst, Melbourne, Vic 8008, Australia

[2] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia

来源：

LANCET | 2010年 / 376卷 / 9752期

关键词：

CHRONIC KIDNEY-DISEASE; PARICALCITOL; HEMODIALYSIS; TRIAL;

D O I：

10.1016/S0140-6736(10)61304-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1521 / 1522

页数：2

共 13 条

[1] Antiproteinuric effect of oral paricalcitol in chronic kidney disease [J].

Agarwal, R ;

Acharya, M ;

Tian, J ;

Hippensteel, RL ;

Melnick, JZ ;

Qiu, P ;

Williams, L ;

Batlle, D .

KIDNEY INTERNATIONAL, 2005, 68 (06) :2823-2828

[2] Paricalcitol reduces albuminuria and inflammation in chronic kidney disease - A randomized double-blind pilot trial [J].

Alborzi, Pooneh ;

Patel, Nina A. ;

Peterson, Carla ;

Bills, Jennifer E. ;

Bekele, Dagim M. ;

Bunaye, Zerihun ;

Light, Robert P. ;

Agarwal, Rajiv .

HYPERTENSION, 2008, 52 (02) :249-255

[3] Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial [J].

de Zeeuw, Dick ;

Agarwal, Rajiv ;

Amdahl, Michael ;

Audhya, Paul ;

Coyne, Daniel ;

Garimella, Tushar ;

Parving, Hans-Henrik ;

Pritchett, Yili ;

Remuzzi, Giuseppe ;

Ritz, Eberhard ;

Andress, Dennis .

LANCET, 2010, 376 (9752) :1543-1551

[4] Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality [J].

Dusso, Adriana ;

Arcidiacono, Maria Vittoria ;

Yang, Jing ;

Tokumoto, Masanori .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2010, 121 (1-2) :193-198

[5] Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial [J].

Fishbane, Steven ;

Chittineni, Harini ;

Packman, Michal ;

Dutka, Paula ;

Ali, Nicole ;

Durie, Nicole .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 54 (04) :647-652

[6] Suppression of renin-angiotensin gene expression in the kidney by paricalcitol [J].

Freundlich, Michael ;

Quiroz, Yasmir ;

Zhang, Zhongyi ;

Zhang, Yan ;

Bravo, Yanauri ;

Weisinger, Jose R. ;

Li, Yan Chun ;

Rodriguez-Iturbe, Bernardo .

KIDNEY INTERNATIONAL, 2008, 74 (11) :1394-1402

[7]

Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI200215219, 10.1172/JCI0215219]

[8] The impact of diabetes mellitus on vitamin D metabolism in predialysis patients [J].

Tanaka, Hirotaka ;

Hamano, Takayuki ;

Fujii, Naohiko ;

Tomida, Kodo ;

Matsui, Isao ;

Mikami, Satoshi ;

Nagasawa, Yasuyuki ;

Ito, Takahito ;

Moriyama, Toshiki ;

Horio, Masaru ;

Imai, Enyu ;

Isaka, Yoshitaka ;

Rakugi, Hiromi .

BONE, 2009, 45 (05) :949-955

[9] Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy [J].

Teng, M ;

Wolf, M ;

Lowrie, E ;

Ofsthun, N ;

Lazarus, JM ;

Thadhani, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (05) :446-456

[10] Mortality risk among hemodialysis patients receiving different vitamin D analogs [J].

Tentori, F. ;

Hunt, W. C. ;

Stidley, C. A. ;

Rohrscheib, M. R. ;

Bedrick, E. J. ;

Meyer, K. B. ;

Johnson, H. K. ;

Zager, P. G. .

KIDNEY INTERNATIONAL, 2006, 70 (10) :1858-1865

← 1 2 →